FEATURED APPLICATION CONTENT

• How EPR Unlocks Missing Dynamics In Pharma And Structural Biology Workflow

  Uncover how EPR spectroscopy fills the conformational gap by capturing dynamic protein motions, refining Cryo-EM models, and revealing hidden structural ensembles for drug discovery.

• Beyond The Bioreactor Scaling CGT Ancillary Materials With The EntoEngine™

  Growing demand for cell and gene therapies is increasing pressure on cytokine production. Explore interleukin manufacturing, quality, consistency, safety, scalability, and supply reliability.

• From Sequence To Scale In Seven Months

  Accelerate recombinant protein development from sequence to scale while maintaining stable expression, manufacturing efficiency, and critical quality attributes.

• Manufacturing Glycosylated Erythropoietin Without 𝛼1,3-Fucosylation

  See how expression hosts affect recombinant EPO glycosylation, bioactivity, and consistency, with reproducible N-glycan profiles and absence of α1,3-linked fucosylation.

• Characterization Of Fly-Derived Prolactin: Insights Into Glycosylation And Activity

  Explore how D. mel-derived human prolactin (hPRL) compares with hPRL expressed in E. coli and HEK293 cells through detailed physico-chemical and biological characterization.

• Rational Design And Material-sparing Strategies For Enabled Intermediates And Drug Products

  A material-sparing strategy integrating formulation mapping, lab-scale spray drying, and compact screening can accelerate risk identification and inform first-round tablet formulation decisions for poorly soluble APIs.

• Navigating The Development Of Dry Powder For Inhalation

  A CDMO-authored framework for navigating dry powder inhaler development, covering target product profile definition, API characterization, particle engineering technology selection, and encapsulation considerations.

• Overcoming The Obstacles Of Spray-Dried Dispersion Scale-Up

  SDD scale-up introduces scale-dependent risks that threaten bioavailability, stability, and manufacturability. This white paper details a model-based framework for managing those risks from early feasibility through commercial production.

• Enzymatic Strategies For Clinical Development Of Antibody-Drug Conjugate

  Despite more than 125 ADCs entering clinical trials, only four have reached approval. This review examines why enzymatic conjugation strategies may change that trajectory.

• Chemoenzymatic N-glycan Conjugation Of Native mAbs Provides Homogeneous, Efficacious ADCs

  A chemoenzymatic two-stage protocol enables DAR2 ADCs from native, non-engineered mAbs via glycan remodeling at Asn-297 and copper-free click chemistry, with in vivo efficacy outperforming a comparable marketed ADC.

• Bringing Novel ADC Formats Into The Clinic: AOC Process Development

  Antibody-oligonucleotide conjugates introduce conjugation and purification challenges that standard ADC process development wasn't designed to solve. This white paper details practical approaches for each.

• AI Enabled Pharmaceutical Cocrystal Screening

  Cocrystal candidate screening is resource-intensive and prone to gaps. This paper examines how AI-based modeling, trained on more than 20,000 data points, can sharpen candidate prioritization without sacrificing scientific rigor.